KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Share-based Compensation (IS)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

BioNTech SE (BNTX) EBT (2018 - 2025)

BioNTech SE's EBT history spans 8 years, with the latest figure at -$264.7 million for Q4 2025.

  • On a quarterly basis, EBT fell 182.24% to -$264.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$1.2 billion, a 58.48% decrease, with the full-year FY2025 number at -$1.2 billion, down 63.94% from a year prior.
  • EBT hit -$264.7 million in Q4 2025 for BioNTech SE, down from $28.9 million in the prior quarter.
  • Over the last five years, EBT for BNTX hit a ceiling of $5.6 billion in Q1 2022 and a floor of -$867.8 million in Q2 2024.
  • Historically, EBT has averaged $1.4 billion across 5 years, with a median of $284.7 million in 2023.
  • Biggest five-year swings in EBT: surged 2199836406.41% in 2021 and later crashed 182.24% in 2025.
  • Tracing BNTX's EBT over 5 years: stood at $5.4 billion in 2021, then tumbled by 39.98% to $3.2 billion in 2022, then tumbled by 77.95% to $713.6 million in 2023, then crashed by 54.89% to $321.9 million in 2024, then crashed by 182.24% to -$264.7 million in 2025.
  • Business Quant data shows EBT for BNTX at -$264.7 million in Q4 2025, $28.9 million in Q3 2025, and -$455.8 million in Q2 2025.